Xingsheng Hu
7PUBLICATIONS
14CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Aug 11, 2025
Efficacy and Safety of Afatinib Plus Bevacizumab as First-Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial.Huiyang Shi, Miaohan Wang, Junling Li
|Dec 20, 2024
Proteomic profiling reveals the significance of lipid metabolism in small cell lung cancer recurrence and metastasis.Haohua Zhu, Huiyang Shi, Jingyu Lu
|Aug 08, 2023
Efficacy and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer: A systematic review and meta-analysis.Yu Feng, Yunxia Tao, Haizhu Chen
|Feb 27, 2023
Efficacy and safety of osimertinib plus anlotinib in advanced non-small-cell lung cancer patients after drug resistance.Mingzhao Wang, Jun Zhao, Tong Chen
|Sep 09, 2022
The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non-small cell lung cancer: A real-world study.Yu Feng, Liling Huang, Haohua Zhu
|Sep 22, 2021
Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.Teng Li, Shouzheng Wang, Jianming Ying
Pageof 2
